Antidepressant Shows Potential in Alleviating Long Covid Fatigue
A new clinical trial has revealed that a widely prescribed antidepressant may offer relief for individuals suffering from the persistent fatigue associated with long Covid. The randomised study, conducted by researchers at the Brazilian Biomedical Research Institute, examined the effects of fluvoxamine, metformin, and a placebo on nearly 400 adults who had experienced fatigue for at least 90 days following a Covid-19 infection.
Study Details and Key Findings
Participants were randomly assigned one of the treatments for a period of 60 days and asked to monitor their fatigue levels using a standard severity scale. The results, published in the Annals of Internal Medicine, indicated that patients taking fluvoxamine reported steady improvements in fatigue and quality-of-life scores over 60 to 90 days. Notably, these individuals experienced fewer side effects compared to those on a placebo.
In contrast, metformin, a medication typically used to lower insulin and blood sugar levels, showed no significant benefit in reducing fatigue. While all treatments were generally safe, fluvoxamine stood out for its favourable side effect profile.
Expert Analysis and Limitations
Professor Christiaan Vinkers from the Amsterdam University Medical Centre, who was not involved in the study, described the findings as promising but cautioned against overinterpretation. He noted that the study appears methodologically solid, with low dropout rates and consistent signals on fatigue and quality of life. However, he highlighted several limitations, including the reliance on self-reported outcomes and the exclusion of patients with depressive or anxiety disorders.
Professor Vinkers emphasised that the study focused primarily on fatigue and did not assess other long Covid features such as post-exertional malaise, autonomic symptoms, or cognitive impairment. He called for replication in broader patient groups with outcomes that capture the full spectrum of long Covid.
Understanding Long Covid and Fluvoxamine
Long Covid is defined as symptoms persisting for longer than 12 weeks after infection, with no current cure available. Experts believe it may be caused by viral persistence, blood clots, and an autoimmune-like response, leading to ongoing issues like fatigue, brain fog, and heart palpitations. In severe cases, these symptoms have left some patients considering assisted suicide.
Fluvoxamine, marketed as Faverin in the UK, belongs to a class of drugs called selective serotonin reuptake inhibitors (SSRIs), which boost serotonin in the brain to improve mood. It is commonly used to treat obsessive-compulsive disorder and social anxiety. The drug also appears to calm the immune system, potentially explaining its effectiveness in easing long Covid fatigue by preventing overreactions.
Broader Context and Future Research
The study's authors suggest fluvoxamine may be a viable treatment for long Covid fatigue, though its long-term effects remain unknown. An important limitation is the lack of assessment of participants' depression history, making it unclear whether the effect was direct or related to underlying depression.
Previous research has indicated that long Covid may stem from an overactive immune system even after the initial infection clears. Similar symptoms have been recorded in post-viral syndromes following other infections like the flu and Epstein-Barr virus. Despite this, some sceptics question the condition's validity due to its varied symptoms and absence of a single diagnostic test.
In 2024, antidepressant prescriptions in England reached a record high of over 91 million, underscoring the relevance of this research. As long Covid continues to affect millions globally, studies like this offer hope for targeted treatments, though further investigation is essential to confirm these findings and explore broader applications.
